Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) shares traded down 0.4% during trading on Thursday . The stock traded as low as $7.80 and last traded at $7.99. 815 shares were traded during mid-day trading, a decline of 74% from the average session volume of 3,077 shares. The stock had previously closed at $8.0250.
Clinuvel Pharmaceuticals Stock Performance
The business has a 50-day simple moving average of $8.22 and a 200-day simple moving average of $7.85.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- When to buy gold (mathematically)
- NEW LAW: Congress Approves Setup For Digital Dollar?
- EXPOSED: The “29% Account”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
